An Increase of Plasma Advanced Oxidation Protein Products Levels Is Associated with Cardiovascular Risk in Incident Peritoneal Dialysis Patients: A Pilot Study

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Gonzalez, Elena ^a   Bajo, Maria Auxiliadora ^a   Carrero, Juan J ^b   Lindholm, Bengt ^b   Grande, Cristina ^a   Sanchez Villanueva, Rafael ^a   Del Peso, Gloria ^a   Diaz Almiron, Mariana ^a   Iglesias, Pedro ^c   Diez, Juan J ^c   Selgas, Rafael ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DIALYSIS; PATIENT TREATMENT; PROTEINS; RISK PERCEPTION;

ADVANCED OXIDATION; BASELINE VALUES; BLOOD SAMPLES; CARDIOVASCULAR RISK; PERITONEAL DIALYSIS; PILOT STUDIES; PLASMA LEVELS; PROINFLAMMATORY;

DIAGNOSIS;

ADVANCED OXIDATION PROTEIN PRODUCT; BIOLOGICAL MARKER;

ADULT; AGED; BLOOD; CARDIOVASCULAR DISEASES; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MIDDLE AGED; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PILOT STUDY; PREVALENCE; RISK FACTOR;

ADULT; ADVANCED OXIDATION PROTEIN PRODUCTS; AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PILOT PROJECTS; PREVALENCE; RISK FACTORS;

EID: 84947447540     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/219569     Document Type: Article

References (24)

1. R. T. Krediet and O. Balafa, "Cardiovascular risk in the peritoneal dialysis patient," Nature Reviews Nephrology, vol. 6, no. 8, pp. 451-460, 2010.
2. P. Stenvinkel, J. J. Carrero, J. Axelsson, B. Lindholm, O. Heimbürger, and Z. Massy, "Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?" Clinical Journal of the American Society of Nephrology, vol. 3, no. 2, pp. 505-521, 2008.
3. H. Alani, A. Tamimi, and N. Tamimi, "Cardiovascular comorbidity in chronic kidney disease: current knowledge and future research needs," World Journal of Nephrology, vol. 3, no. 4, pp. 156-168, 2014.
4. F. Locatelli, B. Canaud,K.-U. Eckardt, P. Stenvinkel,C.Wanner, and C. Zoccali, "Oxidative stress in end-stage renal disease: an emerging treat to patient outcome," Nephrology Dialysis Transplantation, vol. 18, no. 7, pp. 1272-1280, 2003.
5. V. Witko-Sarsat, M. Friedlander, C. Capeillère-Blandin et al., "Advanced oxidation protein products as a novel marker of oxidative stress in uremia," Kidney International, vol. 49, no. 5, pp. 1304-1313, 1996.
6. V. Witko-Sarsat, V. Gausson, and B. Descamps-Latscha, "Are advanced oxidation protein products potential uremic toxins?" Kidney International, Supplement, vol. 63, no. 84, pp. S11-S14, 2003.
7. B. Descamps-Latscha and V. Witko-Sarsat, "Importance of oxidatively modified proteins in chronic renal failure," Kidney International, Supplement, vol. 59, no. 78, pp. S108-S113, 2001.
8. P. Iglesias and J. J. Dez, "Glucación no enzimática de proté?nas en la diabetes mellitus,"Medicina Clinica, vol. 108, no. 1, pp. 23-33, 1997.
9. V. Witko-Sarsat, M. Friedlander, T. N. Khoa et al., "Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure," Journal of Immunology, vol. 161, no. 5, pp. 2524-2532, 1998.
10. V.Witko-Sarsat, T. Nguyen-Khoa, P. Jungers, T. B. Druëke, and B. Descamps-Latscha, "Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia," Nephrology Dialysis Transplantation, vol. 14, supplement 1, pp. 76-78, 1999.
11. A. Y.-M.Wang and K.-N. Lai, "The importance of residual renal function in dialysis patients," Kidney International, vol. 69, no. 10, pp. 1726-1732, 2006.
12. H. Kocak, S. Gumuslu, E. Sahin et al., "Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients," Nephrology, vol. 14, no. 3, pp. 273-280, 2009.
13. R. Sánchez-Villanueva, A. Bajo, G. Del Peso et al., "Higher daily peritoneal protein clearance when initiating peritoneal dialysis is independently associated with peripheral arterial disease (PAD): a possible new marker of systemic endothelial dysfunction?" Nephrology Dialysis Transplantation, vol. 24, no. 3, pp. 1009-1014, 2009.
14. B. Anderstam, B.-H. Ann-Christin, A. Valli, P. Stenvinkel, B. Lindholm, and M. E. Suliman, "Modification of the oxidative stress biomarker AOPP assay: application in uremic samples," Clinica Chimica Acta, vol. 393, no. 2, pp. 114-118, 2008.
15. Z. J. Twardoski, K.D.Nolph, andR.Khan, "Peritoneal equilibration test," Peritoneal Dialysis Bulletin, vol. 7, pp. 138-147, 1987.
16. R. Selgas, M.-J. Fernandez-Reyes, E. Bosque et al., "Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study," American Journal of Kidney Diseases, vol. 23, no. 1, pp. 64-73, 1994.
17. Q. Zhou, S. Wu, J. Jiang et al., "Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischaemic heart disease in maintenance haemodialysis patients," Nephrology, vol. 17, no. 7, pp. 642-649, 2012.
18. H. Xu, I. Cabezas-Rodriguez, A. Rashid Qureshi et al., "Increased levels of modified advanced oxidation protein products are associated with central and peripheral blood pressure in peritoneal dialysis patients," Peritoneal Dialysis International, vol. 1, pp. 1-11, 2014.
19. N. R. Madamanchi, A. Vendrov, and M. S. Runge, "Oxidative stress and vascular disease," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 1, pp. 29-38, 2005.
20. B. B. Dokken, "The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids," Diabetes Spectrum, vol. 21, no. 3, pp. 160-165, 2008.
21. F. J. Pashkow, "Oxidative stress and inflammation in heart disease: do antioxidants have a role in treatment and/or prevention?" International Journal of Inflammation, vol. 2011, Article ID 514623, 9 pages, 2011.
22. B. Descamps-Latscha, V. Witko-Sarsat, T. Nguyen-Khoa et al., "Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients," The American Journal of Kidney Diseases, vol. 45, no. 1, pp. 39-47, 2005.
23. M. Skvarilová, A. Bulava, D. Stejskal, S. Adamovská, and J. Bartek, "Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome," Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, vol. 149, no. 1, pp. 83-87, 2005.
24. R. Furuya, H. Kumagai, M. Odamaki, M. Takahashi, A. Miyaki, and A. Hishida, "Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients," Nephron Clinical Practice, vol. 112, no. 4, pp. c255-c261, 2009.